Abstract
Polypeptides and proteins may undergo misfolding processes resulting in aggregates: oligomers and fibrils possessing toxic properties. In most cases a beta-structure will be formed with high tendency to form suprachemical structures, assemblies. The aggregation grade might play crucial role in the biological activities of protein assemblies. Protein aggregates bind to receptors or receptor complexes of neuronal and glial cells and activate signal transduction pathways. Beta amyloid may interact with Wnt receptors as well as increases the intracellular Ca-ion level in neurons. GSK-3beta activation causes tau-hyperphosphorylation and collaps of the microtubular system. β-amyloid triggers also a CD36 dependent signaling cascade and activates microglia. Other misfolded protein assemblies of alpha-synuclein, huntingtin and prion proteins similarly interact with receptor complexes and disturb signal transduction. Rational drug design may start after understanding these signalisation disturbances. Novel drugs will prevent receptor interaction with misfolded protein aggregates.
Keywords: Misfolded protein, beta-amyloid, receptor mediation, signal transduction, neurodegenerative disorders
Current Signal Transduction Therapy
Title: Polypeptide and Protein Aggregates with Neurotoxic Properties in Neurodegenerative Disorders: Emphasis on β-Amyloid-Induced Dysfunction of Receptor-Mediated Signal Transduction Pathways
Volume: 1 Issue: 1
Author(s): Yann Verdier and Botond Penke
Affiliation:
Keywords: Misfolded protein, beta-amyloid, receptor mediation, signal transduction, neurodegenerative disorders
Abstract: Polypeptides and proteins may undergo misfolding processes resulting in aggregates: oligomers and fibrils possessing toxic properties. In most cases a beta-structure will be formed with high tendency to form suprachemical structures, assemblies. The aggregation grade might play crucial role in the biological activities of protein assemblies. Protein aggregates bind to receptors or receptor complexes of neuronal and glial cells and activate signal transduction pathways. Beta amyloid may interact with Wnt receptors as well as increases the intracellular Ca-ion level in neurons. GSK-3beta activation causes tau-hyperphosphorylation and collaps of the microtubular system. β-amyloid triggers also a CD36 dependent signaling cascade and activates microglia. Other misfolded protein assemblies of alpha-synuclein, huntingtin and prion proteins similarly interact with receptor complexes and disturb signal transduction. Rational drug design may start after understanding these signalisation disturbances. Novel drugs will prevent receptor interaction with misfolded protein aggregates.
Export Options
About this article
Cite this article as:
Verdier Yann and Penke Botond, Polypeptide and Protein Aggregates with Neurotoxic Properties in Neurodegenerative Disorders: Emphasis on β-Amyloid-Induced Dysfunction of Receptor-Mediated Signal Transduction Pathways, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269208
DOI https://dx.doi.org/10.2174/157436206775269208 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Type 2 Diabetes Mellitus: New Genetic Insights will Lead to New Therapeutics
Current Genomics Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Current Neuropharmacology Molecular Pathology in Neurodegenerative Diseases
Current Drug Targets Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Current Gene Therapy Plant Polyphenols and Oral Health: Old Phytochemicals for New Fields
Current Medicinal Chemistry Ladostigil: A Novel Multimodal Neuroprotective Drug with Cholinesterase and Brain-Selective Monoamine Oxidase Inhibitory Activities for Alzheimers Disease Treatment
Current Drug Targets Translational Multimodality Neuroimaging
Current Drug Targets Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Pupil Response Biomarkers Distinguish Amyloid Precursor Protein Mutation Carriers from Non-Carriers
Current Alzheimer Research Age-Related Changes in Motor Cortical Properties and Voluntary Activation of Skeletal Muscle
Current Aging Science Relevance of Dopamine D2/Neurotensin NTS1 and NMDA/Neurotensin NTS1 Receptor Interaction in Psychiatric and Neurodegenerative Disorders
Current Medicinal Chemistry Inducers of Heme Oxygenase-1
Current Pharmaceutical Design GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Brain local and regional neuroglial alterations in Alzheimer´s Disease: cell types, responses and implications.
Current Alzheimer Research Coping with Stress During Aging: The Importance of a Resilient Brain
Current Neuropharmacology The Metabotropic Glutamate Receptor System: G-Protein Mediated Pathways that Modulate Neuronal and Vascular Cellular Injury
Current Medicinal Chemistry - Central Nervous System Agents Molecular Imaging of Stem Cell Transplantation for Neurodegenerative Diseases
Current Pharmaceutical Design